<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Lupus</journal-id>
      <journal-id journal-id-type="iso-abbrev">Lupus</journal-id>
      <journal-id journal-id-type="publisher-id">LUP</journal-id>
      <journal-id journal-id-type="hwp">splup</journal-id>
      <journal-title-group>
        <journal-title>Lupus</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0961-2033</issn>
      <issn pub-type="epub">1477-0962</issn>
      <publisher>
        <publisher-name>SAGE Publications</publisher-name>
        <publisher-loc>Sage UK: London, England</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23864039</article-id>
      <article-id pub-id-type="pmc">4107795</article-id>
      <article-id pub-id-type="doi">10.1177/0961203313497116</article-id>
      <article-id pub-id-type="publisher-id">10.1177_0961203313497116</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Grand Round</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Heart failure in a woman with SLE, anti-phospholipid syndrome and Fabry&#x2019;s
disease</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Nandagudi</surname>
            <given-names>A</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-0961203313497116">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Jury</surname>
            <given-names>EC</given-names>
          </name>
          <xref ref-type="aff" rid="aff2-0961203313497116">2</xref>
          <xref ref-type="corresp" rid="corresp1-0961203313497116"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alonzi</surname>
            <given-names>D</given-names>
          </name>
          <xref ref-type="aff" rid="aff3-0961203313497116">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Butters</surname>
            <given-names>TD</given-names>
          </name>
          <xref ref-type="aff" rid="aff3-0961203313497116">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hughes</surname>
            <given-names>S</given-names>
          </name>
          <xref ref-type="aff" rid="aff4-0961203313497116">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Isenberg</surname>
            <given-names>DA</given-names>
          </name>
          <xref ref-type="aff" rid="aff1-0961203313497116">1</xref>
          <xref ref-type="aff" rid="aff2-0961203313497116">2</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1-0961203313497116"><label>1</label>Department of Rheumatology, University College Hospital, UK</aff>
      <aff id="aff2-0961203313497116"><label>2</label>Centre for Rheumatology Research, Department of Medicine, University College
London, UK</aff>
      <aff id="aff3-0961203313497116"><label>3</label>Oxford Glycobiology Institute, Department of Biochemistry, University of
Oxford, UK</aff>
      <aff id="aff4-0961203313497116"><label>4</label>Department of Histopathology, University College Hospital, UK</aff>
      <author-notes>
        <corresp id="corresp1-0961203313497116">Elizabeth Jury, University College London, 5
University Street, London, W1CE 6JF, UK. Email: <email>e.jury@ucl.ac.uk</email></corresp>
        <fn fn-type="other" id="fn1-0961203313497116">
          <p>A.N. and E.C.J. share first authorship.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>9</month>
        <year>2013</year>
      </pub-date>
      <volume>22</volume>
      <issue>10</issue>
      <fpage>1070</fpage>
      <lpage>1076</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>12</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>17</day>
          <month>6</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2013 Reprints and permissions:
sagepub.co.uk/journalsPermissions.nav</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder content-type="sage">SAGE Publications</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 3.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/3.0/">http://www.creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits
non-commercial use, reproduction and distribution of the work without further permission
provided the original work is attributed as specified on the SAGE and Open Access
page(<ext-link ext-link-type="uri" xlink:href="http://www.uk.sagepub.com/aboutus/openaccess.htm">http://www.uk.sagepub.com/aboutus/openaccess.htm</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We describe a female patient with systemic lupus erythematosus (SLE) also diagnosed with
Fabry&#x2019;s disease and anti-phospholipid antibody syndrome (APS). SLE and Fabry&#x2019;s disease are
both systemic diseases with variable clinical presentations. Recent studies have shown a
relatively high incidence of late onset Fabry&#x2019;s disease in female heterozygous
individuals, suggesting that this condition could be under-diagnosed. We discuss a
possible association between SLE and Fabry&#x2019;s disease and consider the role of lipid
abnormalities in the pathogenesis of SLE.</p>
      </abstract>
      <kwd-group>
        <kwd>SLE</kwd>
        <kwd>Fabry&#x2019;s disease</kwd>
        <kwd>Gb3</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="sec1-0961203313497116">
      <title>Introduction</title>
      <p>This case describes a female patient with systemic lupus erythematosus (SLE) and
antiphospholipid antibody syndrome (APS). The patient went on to develop atypical symptoms
of heart disease and was diagnosed with the lysosomal storage disease, Fabry&#x2019;s disease (FD),
which is characterized by the accumulation of lipids in organs and tissues. SLE and FD are
both systemic diseases with variable clinical presentations. Recent studies have shown a
relatively high incidence of late onset FD in female heterozygous individuals, suggesting
that this condition could be under-diagnosed. Interestingly, the pattern of organ
involvement in patients with SLE and FD can be similar and this case highlights similarities
in disease pathogenesis between the two conditions. We discuss a possible association
between SLE and FD and consider the role of lipid abnormalities in the pathogenesis of
SLE.</p>
      <sec id="sec2-0961203313497116" sec-type="cases">
        <title>Case presentation</title>
        <p>A 38-year-old Caucasian woman presented with exertional chest pain with shortness of
breath.</p>
        <sec id="sec3-0961203313497116">
          <title>History of present illness</title>
          <p>The patient was diagnosed with SLE in 1987 with an unusual presentation including
arthralgia and loose stools. At diagnosis her autoimmune profile was diffuse pattern
antinuclear antibody 1/640, positive anti-double-stranded (ds)DNA, negative extractable
nuclear antigens (ENA, including anti-Ro) and low complement C3 and C4. Antiphospholipid
antibodies (aPL) were negative at diagnosis but became positive in 1996. She had a
history of photosensitivity, malar rash, occasional mouth ulcers, increased sweating and
joint pain (knees, hands and spine). She had no constitutional symptoms or history
suggestive of active infection and no neurological symptoms, cataract, tinnitus, hearing
loss or angiokeratoma. Her father died at age 65 with congestive cardiac failure and her
mother was alive at age 67 having had a subarachnoid haemorrhage but she had no other
cardiovascular risk factors (non-smoker with normal serum cholesterol). The patient had
a history of secondary Sj&#xF6;gren&#x2019;s syndrome, sensory epilepsy and migraine.</p>
          <p>Treatment included hydroxycholoroquine (1987&#x2013;2007) 400&#x2009;mg/day, azathioprine (from 1990)
100&#x2009;mg and prednisolone 5&#x2009;mg. She was also on sodium valproate, cyclizine,
amitriptyline, losartan and ibuprofen and had been reviewed routinely by a cardiologist
in 1988 with no evidence of heart disease and a normal electrocardiogram (ECG). In a
second review in 1999 the echocardiogram demonstrated normal posterior and
inter-ventricular septum wall thickness of 0.9 cms. The valves were normal and the
function was good at that stage.</p>
          <p>In April 2002 she presented with shortness of breath and exertional chest pain when
walking upstairs or on inclines. The pain was central and radiated to the left arm. She
also complained of palpitations, describing a &#x2018;pounding sensation&#x2019; which improved with
losartan. She gave no history of syncope but occasionally complained of presyncope when
standing up rapidly, and tiredness. In June 2002 she had distinct changes in her
exercise capacity and was moderately hypertensive; she was referred to a
cardiologist.</p>
        </sec>
        <sec id="sec4-0961203313497116">
          <title>Physical examination</title>
          <p>She was afebrile and moderately hypertensive (140/70), pulse was 90, regular and venous
pressure was elevated. Other vital signs were stable. She weighed 80 kg and her height
was 167.2&#x2009;cm. There was peripheral oedema but no clubbing. She had a butterfly facial
rash but no angiokeratoma. Joint exam was normal with no evidence of synovitis. The
reflexes were normal and symmetrical and there was no sensory deficit. There was 2/6
ejection systolic murmur at the left sternal edge and basal crepitations on chest
examination. There was no hepatosplenomegaly.</p>
        </sec>
        <sec id="sec5-0961203313497116">
          <title>Investigations</title>
          <p>Her routine full blood count, urea, electrolytes, liver functions, thyroid function and
urinary protein creatinine ratio were normal. ECG showed marked QRS changes with
hypertrophy, mild QRS broadening and widespread anterolateral ST segment abnormalities.
There was sinus rhythm with voltage criteria for left ventricle hypertrophy and normal
PR interval. Echocardiogram demonstrated a small left ventricular (LV) cavity with
concentric LV hypertrophy with a maximal thickness of 1.7&#x2009;cm. She had complete LV
obliteration on apical view but there was no significant outflow gradient. She had
evidence of impaired relaxation on the transmitral Doppler. There was also evidence of
moderate right ventricular hypertrophy. The valves were thin, mobile with no lesions and
no pericardial effusion. Coronary angiogram demonstrated normal coronary arteries.</p>
        </sec>
        <sec id="sec6-0961203313497116">
          <title>Diagnosis</title>
          <p>Echocardiograph showed cardiomyopathy (CM) changes (concentric hypertrophy with
posterior wall and interventricular septum thickness of 2&#x2009;cm which was absent in 1999
with the thickness being 0.9&#x2009;cm). The heart biopsy showed no evidence of amyloid. The
sarcoplasmic vacuolation and myofibrillary loss of myocytes seen in the heart biopsy was
due to glycosphingolipid deposition (<xref ref-type="fig" rid="fig1-0961203313497116">Figure 1(a)</xref>) and massive deposition of electron-dense glycosphingolipid in the
form of myelin figures in the myocyte sarcoplasm (<xref ref-type="fig" rid="fig1-0961203313497116">Figure 1(b)</xref>). A similar appearance can be observed
in hydroxychloroquine-associated CM (hydroxycloroquine inhibits the function of
lysosomal enzymes<sup><xref rid="bibr1-0961203313497116" ref-type="bibr">1</xref></sup>). However, when myelin figures are present in large numbers, FD should be
considered and confirmed by more specific investigations.<fig id="fig1-0961203313497116" position="float"><label>Figure 1</label><caption><p>Heart biopsy from the systemic lupus erythematosus (SLE) patient showing
pathology consistent with Fabry&#x2019;s disease. (a) Haematoxylin and eosin-stained
light micrograph section showing sarcoplasmic vacuolation and myofibrillary loss
of myocytes. Magnification&#x2009;&#xD7;&#x2009;200 and (b) Electron micrograph showing
electron-dense glycosphingolipid in the form of myelin figures in the myocyte
sarcoplasm.</p></caption><graphic xlink:href="10.1177_0961203313497116-fig1"/></fig>
</p>
          <p>FD is an X-linked deficiency of the enzyme &#x3B1;-galactosidase A (GLA), resulting in
accumulation of the glycosphingolipid globotriaosylceramide (Gb3) in organs and tissues.
GLA activity was low in this patient at 39&#x2009;nmol/hr/mg protein (normal range 33&#x2013;134), and
genetic testing in August 2003 showed a rare P343L mutation in the GLA enzyme,
confirming the diagnosis.</p>
        </sec>
        <sec id="sec7-0961203313497116">
          <title>Treatment and subsequent course</title>
          <p>The patient was treated with enzyme-replacement therapy (ERT), agalsidase beta
(Fabrazyme), aspirin and diltiazem. Hydroxychloroquine was stopped in November 2007 when
a maculopathy was suspected and she has been reviewed regularly since by the
ophthalmologists.</p>
          <p>In 2008 her echocardiogram showed mild LV dilatation with hypokinesis of the anterior
and inferior septum (ejection fraction 50%, LV end diastolic diameter (LVEDD) 53&#x2009;mm, LV
end-systolic diameters (LVESD) 39&#x2009;mm, left atrium 34&#x2009;mm, septum 8&#x2009;mm). Tissue Doppler
velocities were reduced at the mitral valve annulus and transmitral inflow confirmed
mild diastolic dysfunction. Right heart size and function was normal and there was no
relevant valvular abnormality. There was a thin organized layer of pericardial fibrin
with a small chronic pericardial effusion. The cardiac magnetic resonance imaging (MRI)
showed normal myocardial wall thickness with an ejection fraction of 35%. There was
extensive late gadolinium enhancement affecting 50% of the myocardium. It was mainly
mid-myocardial and in some areas transmural. There was a small pericardial effusion.</p>
          <p>She suffered a myocardial infarction (MI) with a distal anterior descending artery
thrombus in June 2009. Her blood tests showed increased IgM aPL 32 mplu/ml (normal range
(nr) 0&#x2013;9) and raised IgM anti-&#x3B2;2 glycoprotein I (&#x3B2;2GPI) antibody 111 U/ml (nr&#x2009;=&#x2009;0&#x2013;12).
She was treated with atorvastatin (80&#x2009;mg/day), aspirin and clopidogrel, which was then
changed to warfarin (international normalized ratio (INR) 3&#x2013;4) following discussions
with haematologists and rheumatologists. An unstable INR on warfarin treatment, probably
linked to variations in her ibuprofen and fluconazole, led to the replacement of
warfarin with dalteparin 15,000 units subcutaneously (sc)/day.</p>
          <p>In September 2011 she suffered a cerebrovascular accident affecting the right middle
cerebral artery whilst on dalteparin. She was started on clopidogrel temporarily and
then the dalteparin dose was gradually increased to 8500 units twice daily. Her lupus
disease activity remains relatively inactive clinically although aPL, anti-&#x3B2;2 GPI
antibodies and lupus anticoagulant continue to be positive. Her dsDNA antibody remained
positive (between 160 and 200&#x2009;IU/ml, normal range &#x2264;50) and complement C3 level varied
between 0.80 and 0.96&#x2009;g/l (normal range 0.9&#x2013;1.80). Her liver and kidney function have
remained stable throughout the course.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="sec8-0961203313497116">
      <title>Discussion</title>
      <sec id="sec9-0961203313497116">
        <title>Differential diagnosis</title>
        <p>The clinical presentation could have been due to SLE-related heart disease, APS or
atherosclerosis and coronary artery disease (CAD). Rarer causes of heart failure include
infection, infiltrative lesions, arrhythmias, drugs and toxins. The coronary angiogram was
normal and there was no evidence of hypokinesia or akinesia on echocardiogram. However,
the echocardiogram did reveal increased ventricle thickness suggestive of an infiltrative
process such as amyloidosis or a storage disease</p>
      </sec>
      <sec id="sec10-0961203313497116">
        <title>SLE-related heart disease</title>
        <p>Cardiac involvement in lupus is one of the major causes of morbidity and mortality with
SLE. It can involve all three layers of the heart &#x2013; pericardium, myocardium and
endocardium. Clinical (symptomatic) pericarditis is seen in approximately 25% of SLE
patients during the course of their disease; however, asymptomatic pericardial effusion is
more common and is usually detected on echocardiogram. It occurs more frequently at SLE
onset or during relapse, although it can occur at any time of the disease.<sup><xref rid="bibr2-0961203313497116" ref-type="bibr">2</xref></sup> Episodes can be isolated or recurrent<sup><xref rid="bibr3-0961203313497116" ref-type="bibr">3</xref></sup> and complications include cardiac tamponade, constrictive pericarditis and purulent
pericarditis.</p>
        <p>Myocarditis is uncommon in SLE, occurring in &lt;10% of patients although subclinical
disease is more frequent.<sup><xref rid="bibr4-0961203313497116" ref-type="bibr">4</xref></sup> Clinical features include dyspnoea, tachycardia, arrhythmias which can progress to
ventricular dysfunction, dilated CM and heart failure. There are no typical findings on
ECG, and cardiac enzymes may be normal. Large echocardiogram series have found frequencies
of global hypokinesis between 5% and 20%. However, segmental areas of hypokinesis can also
be indicative of the disease.<sup><xref rid="bibr5-0961203313497116" ref-type="bibr">5</xref></sup> Magnetic resonance has proved useful in diagnosing myocardial involvement, even at
the preclinical stage.<sup><xref rid="bibr6-0961203313497116" ref-type="bibr">6</xref></sup> However, endomyocardial biopsy remains the investigation of choice.</p>
        <p>The notion that lupus myocarditis is an immune complex-mediated disease is supported by
immunofluorescence studies demonstrating fine granular immune complex and complement
deposition in the walls and perivascular tissues of myocardial blood vessels. Some reports
demonstrate an association between anti-SSA/Ro antibodies and myocarditis.<sup><xref rid="bibr7-0961203313497116" ref-type="bibr">7</xref></sup>
</p>
      </sec>
      <sec id="sec11-0961203313497116">
        <title>Atherosclerosis and CAD</title>
        <p>The prevalence of CAD ranges from 6% to 10% in SLE patients and the risk of developing
any CAD is four to eight times higher than in control subjects.<sup><xref rid="bibr8-0961203313497116" ref-type="bibr">8</xref><xref rid="bibr9-0961203313497116" ref-type="bibr"/><xref rid="bibr10-0961203313497116" ref-type="bibr"/>&#x2013;<xref rid="bibr11-0961203313497116" ref-type="bibr">11</xref></sup> In young women with SLE, the risk of MI is increased up to 50-fold.<sup><xref rid="bibr12-0961203313497116" ref-type="bibr">12</xref></sup> Traditional risk factors (hypertension, hyperlipidaemia, smoking, obesity, diabetes
mellitus), non-traditional risk factors (e.g. autoimmune inflammation) and corticosteroids
increase the risk of CAD.</p>
      </sec>
      <sec id="sec12-0961203313497116">
        <title>Heart involvement in APS</title>
        <p>Heart valve lesions (vegetation, valve thickening and dysfunction) are frequently
reported in patients with APS with and without SLE<sup><xref rid="bibr13-0961203313497116" ref-type="bibr">13</xref></sup> and in those with aPL alone.<sup><xref rid="bibr14-0961203313497116" ref-type="bibr">14</xref></sup> Libman-Sacks endocarditis is a feature of APS. SLE and APS have similar valve
abnormalities, varying from minimal thickening and/or vegetations to severe valve
distortion and dysfunction. Hojnik et&#xA0;al.<sup><xref rid="bibr14-0961203313497116" ref-type="bibr">14</xref></sup> reviewed echocardiographic studies of primary APS patients and reported 32%&#x2013;38%
prevalence of valve lesions most frequently involving left-sided valves (mitral more
common than aortic), whereas Libman-Sacks commonly involves the tricuspid valve. Turiel et&#xA0;al.<sup><xref rid="bibr15-0961203313497116" ref-type="bibr">15</xref></sup> demonstrated valve abnormalities in 82% of primary APS patients and mitral valve
thickening in 63%, using trans-oesophageal echocardiography (TEE). Erdogan et&#xA0;al.<sup><xref rid="bibr16-0961203313497116" ref-type="bibr">16</xref></sup> demonstrated cardiac involvement in 84% of primary APS patients and mitral
regurgitation in 77.4%. Valvular disease is mostly mild and asymptomatic; only rarely
(4%&#x2013;6%) patients develop valve disease severe enough to require surgical treatment.</p>
      </sec>
      <sec id="sec13-0961203313497116">
        <title>Atherosclerosis and CAD in APS</title>
        <p>APS patients suffer from an increased rate of cardiovascular accidents: It is the
presenting manifestation in 2.8% of patients and up to 5.5% of APS patients suffer an MI
during the course of their disease.<sup><xref rid="bibr13-0961203313497116" ref-type="bibr">13</xref></sup> Correlation between serum levels of aPL and anti-&#x3B2;2GPI antibodies and the incidence
and severity of acute coronary syndrome, MI and stroke was shown by Veres and others.<sup><xref rid="bibr17-0961203313497116" ref-type="bibr">17</xref></sup> Lupus anticoagulant and anti-&#x3B2;2GPI antibodies are the risk factors for MI in the
assessment of SLE patient cohorts.<sup><xref rid="bibr18-0961203313497116" ref-type="bibr">18</xref>,<xref rid="bibr19-0961203313497116" ref-type="bibr">19</xref></sup>
</p>
      </sec>
      <sec id="sec14-0961203313497116">
        <title>Antimalarial (hydroxychloroquine/chloroquine)-induced CM</title>
        <p>According to case reports, clinical heart failure and restrictive CM are extremely rare
but potentially life-threatening complications associated with long-term treatment with
chloroquine or hydroxychloroquine.<sup><xref rid="bibr20-0961203313497116" ref-type="bibr">20</xref><xref rid="bibr21-0961203313497116" ref-type="bibr"/>&#x2013;<xref rid="bibr22-0961203313497116" ref-type="bibr">22</xref></sup> Other cardiac complications include myocardial thickening, cardiac insufficiency
and conduction disorders.<sup><xref rid="bibr23-0961203313497116" ref-type="bibr">23</xref></sup> The interval between treatment commencement and development of cardiac
complications ranges from seven months to 25 years and the total cumulative doses ranges
from 292&#x2009;g to 4380&#x2009;g for chloroquine.<sup><xref rid="bibr24-0961203313497116" ref-type="bibr">24</xref>,<xref rid="bibr25-0961203313497116" ref-type="bibr">25</xref></sup>
</p>
        <p>A finding of restrictive physiology on two-dimensional echocardiogram should prompt the
clinician to consider various aetiologies and investigate accordingly. The pathologic
findings associated with antimalarial cardiotoxicity are similar to FD and secondary amyloidosis.<sup><xref rid="bibr24-0961203313497116" ref-type="bibr">24</xref>,<xref rid="bibr26-0961203313497116" ref-type="bibr">26</xref><xref rid="bibr27-0961203313497116" ref-type="bibr"/>&#x2013;<xref rid="bibr28-0961203313497116" ref-type="bibr">28</xref></sup> Cardiac biopsy with findings such as vacuolar myopathy, myeloid bodies and
curvilinear bodies can prove helpful in cases with new onset heart failure. Clinical
resolution and significant regression of diastolic dysfunction are demonstrated with
discontinuation of chloroquine.</p>
      </sec>
      <sec id="sec15-0961203313497116">
        <title>FD</title>
        <p>FD is an X-linked deficiency of the lysosomal enzyme GLA resulting in the accumulation of
the glycosphingolipid Gb3 in organs and tissues. Accumulation of Gb3 leads to progressive
organ failure and premature death although the precise pathogenic mechanisms leading to
clinical symptoms are not completely understood.<sup><xref rid="bibr29-0961203313497116" ref-type="bibr">29</xref></sup> Typical manifestations include angiokeratoma, sweating disturbances, neuropathic
pain, hearing impairment as well as heart, kidney and central nervous system involvement.<sup><xref rid="bibr30-0961203313497116" ref-type="bibr">30</xref></sup> Clinical onset in homozygous males (with very low levels of GLA activity) is severe
occurring in childhood; however, heterozygous females (with intermediate GLA enzyme
activity) have late onset disease or may be asymptomatic. Incidence of classic onset
disease is rare (one in 37,000); however, recent neonatal screening studies show that late
onset incidence is higher than expected (one in 3100 live births), indicating that the
true prevalence of FD is underestimated.<sup><xref rid="bibr31-0961203313497116" ref-type="bibr">31</xref></sup> Furthermore, it has been suggested that patients with renal, cerebral and cardiac
insufficiency of unknown cause might have FD.<sup><xref rid="bibr32-0961203313497116" ref-type="bibr">32</xref></sup> Interestingly, the pattern of organ involvement in patients with SLE and FD can be similar.<sup><xref rid="bibr33-0961203313497116" ref-type="bibr">33</xref></sup>
</p>
        <p>The coexistence of FD and autoimmunity including SLE and rheumatoid arthritis has been
described previously.<sup><xref rid="bibr33-0961203313497116" ref-type="bibr">33</xref><xref rid="bibr34-0961203313497116" ref-type="bibr"/><xref rid="bibr35-0961203313497116" ref-type="bibr"/>&#x2013;<xref rid="bibr36-0961203313497116" ref-type="bibr">36</xref></sup> Patients have presented with different symptoms (including eye, renal and cardiac
involvement) consistent with the heterogeneous nature of FD. Here we describe a patient
with SLE and FD complicated by APS. The patient&#x2019;s severe myocardial dysfunction, not being
consistent with APS or other conditions, led to the diagnosis which was confirmed by
testing GLA enzyme activity (which was low, although this is not always the case in
patients) and by genetic testing that revealed an unusual GLA polymorphism (P343L)
contributing GLA enzyme deficiency.<sup><xref rid="bibr32-0961203313497116" ref-type="bibr">32</xref></sup>
</p>
        <p>Recently, the patient suffered an MI with a distal anterior descending artery thrombus.
Stroke, thrombophilia and the presence of autoantibodies, including &#x2018;lupus-associated&#x2019;
antibodies to dsDNA, ENA and phospholipids,<sup><xref rid="bibr37-0961203313497116" ref-type="bibr">37</xref></sup> can be features of patients with FD. Since the prevalence of aPL in Fabry&#x2019;s
patients is up to 45%<sup><xref rid="bibr37-0961203313497116" ref-type="bibr">37</xref></sup> compared to around 30% in lupus patients,<sup><xref rid="bibr38-0961203313497116" ref-type="bibr">38</xref></sup> it is difficult to assess whether the presence of aPL in this patient resulted from
the FD or the APS. However, it seems likely that high levels of aPL that developed between
2002 and 2009 may well have contributed to the MI suffered in 2009.</p>
        <p>Originally it was believed that pathology in FD was caused by increased lipid (Gb3)
deposition in various organs. However, recent work suggests that Gb3 is immunogenic and
provides a continuous stimulus, potentially by changing the nature of lymphocyte cell
membranes, thereby creating an environment able to sustain autoimmune responses.<sup><xref rid="bibr30-0961203313497116" ref-type="bibr">30</xref></sup> These observations are consistent with what is known about defects in immune cell
function in patients with SLE.<sup><xref rid="bibr39-0961203313497116" ref-type="bibr">39</xref></sup> SLE patients are characterized by an altered composition of lymphocyte cell
membrane lipids, including Gb3, that can increase their activation.<sup><xref rid="bibr39-0961203313497116" ref-type="bibr">39</xref></sup> Furthermore, increased accumulation of glycolipids in the cell membrane of
lymphocytes increases oxidative stress and the formation of reactive oxygen species, both
factors that influence the inflammatory response and contribute to increased
cardiovascular risk.<sup><xref rid="bibr32-0961203313497116" ref-type="bibr">32</xref></sup> Since patients with SLE are associated with an unexplained increased cardiovascular
risk (up to 10 times overall and up to 50 times in female patients aged between 35 to 44,<sup><xref rid="bibr12-0961203313497116" ref-type="bibr">12</xref>,<xref rid="bibr40-0961203313497116" ref-type="bibr">40</xref></sup> there may be a case for screening certain SLE patients for Gb3 and GLA enzyme
activity, for example, those with unexplained cardiac symptoms.</p>
        <p>Unlike the previous reports, the patient described here was treated with agalsidase beta,
a relatively new therapy for lysosomal storage diseases.<sup><xref rid="bibr32-0961203313497116" ref-type="bibr">32</xref></sup> Enzyme-replacement therapy (ERT) (agalsidase alfa or agalsidase beta) is able to
reduce Gb3 expression in the serum; this was the case in this patient as shown in <xref ref-type="fig" rid="fig2-0961203313497116">Figure 2</xref> but its effect on disease
symptoms can vary. Both drugs have been shown to improve cardiac involvement in FD,<sup><xref rid="bibr41-0961203313497116" ref-type="bibr">41</xref>,<xref rid="bibr42-0961203313497116" ref-type="bibr">42</xref></sup> which was also the case in our patient (<xref ref-type="fig" rid="fig3-0961203313497116">Figure 3</xref>). However, as mentioned our patient did go
on to have an MI with a distal anterior descending artery thrombus. Relevant to this, one
in&#xA0;vitro study reported that ERT may contribute to endothelial damage, which could explain
why strokes continue to occur in patients treated with ERT.<sup><xref rid="bibr43-0961203313497116" ref-type="bibr">43</xref></sup>&#x2009; <fig id="fig2-0961203313497116" position="float"><label>Figure 2</label><caption><p>Reduced serum expression of glycosphingolipid globotriaosylceramide (Gb3) following
enzyme-replacement therapy (ERT). Glycosphingolipids (GSLs) were isolated from serum
samples taken before and after commencement of ERT and analysed by high-performance
liquid chromatography (HPLC).<sup><xref rid="bibr44-0961203313497116" ref-type="bibr">44</xref></sup> Results were compared to specific GSL standards and the ratio of Gb3 to GM3
(a GSL whose levels are not affected by AGL deficiency) was calculated. (a) HPLC
plots from before ERT compared to the GSL standards and (b) plot of the ratio
between of Gb3 and GM3 expression in the serum before and after ERT.</p></caption><graphic xlink:href="10.1177_0961203313497116-fig2"/></fig>
<fig id="fig3-0961203313497116" position="float"><label>Figure 3</label><caption><p>Interventricular septum thickness is reduced after enzyme-replacement therapy
(ERT). Plot of septum thickness levels before and after commencement of ERT.</p></caption><graphic xlink:href="10.1177_0961203313497116-fig3"/></fig>
</p>
      </sec>
    </sec>
    <sec sec-type="conclusions" id="sec16-0961203313497116">
      <title>Conclusion</title>
      <p>This case highlights similarities in the disease pathogenesis between patients with SLE and
FD. The co-existence of FD and SLE may be more common than previously believed. Furthermore,
defects in lipid biosynthesis, such as is seen in FD, could contribute to the development of
autoimmunity. Finally, this case reminds the physician that although lupus is a complicated
disease on its own, approximately 30% of patients also present with a second (or more)
concomitant autoimmune disease which adds to the complication. Thus the diagnosis of lupus
is just the beginning of the story.</p>
    </sec>
    <sec id="sec17-0961203313497116">
      <title>Final diagnosis</title>
      <p>SLE and APS with Fabry&#x2019;s disease.</p>
    </sec>
    <sec id="sec18-0961203313497116">
      <title>Ethical approval</title>
      <p>The patient provided informed written consent for this case to be presented. Other
experimental work was approved by the ethics committee of University College Hospital London
(00/0241).</p>
    </sec>
  </body>
  <back>
    <sec id="sec19-0961203313497116">
      <title>Funding</title>
      <p>ECJ is supported by a Arthritis Research UK Career Development Grant (grant number
18106).</p>
    </sec>
    <sec id="sec20-0961203313497116">
      <title>Conflict of interest</title>
      <p>None declared.</p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="bibr1-0961203313497116">
        <label>1</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>DJ</given-names><suffix>Jr</suffix></name><name><surname>Gluzman</surname><given-names>IY</given-names></name><name><surname>Russell</surname><given-names>DG</given-names></name><name><surname>Goldberg</surname><given-names>DE</given-names></name></person-group>
<article-title>On the molecular mechanism of chloroquine&#x2019;s antimalarial
action</article-title>. <source>Proc Natl Acad Sci U S A</source>
<year>1996</year>; <volume>93</volume>:
<fpage>11865</fpage>&#x2013;<lpage>118670</lpage><pub-id pub-id-type="pmid">8876229</pub-id></mixed-citation>
      </ref>
      <ref id="bibr2-0961203313497116">
        <label>2</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doria</surname><given-names>A</given-names></name><name><surname>Iaccarino</surname><given-names>L</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name><surname>Atzeni</surname><given-names>F</given-names></name><name><surname>Turriel</surname><given-names>M</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>
<article-title>Cardiac involvement in systemic lupus
erythematosus</article-title>. <source>Lupus</source>
<year>2005</year>; <volume>14</volume>: <fpage>683</fpage>&#x2013;<lpage>686</lpage><pub-id pub-id-type="pmid">16218467</pub-id></mixed-citation>
      </ref>
      <ref id="bibr3-0961203313497116">
        <label>3</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brigden</surname><given-names>W</given-names></name><name><surname>Bywaters</surname><given-names>EG</given-names></name><name><surname>Lessof</surname><given-names>MH</given-names></name><name><surname>Ross</surname><given-names>IP</given-names></name></person-group>
<article-title>The heart in systemic lupus erythematosus</article-title>.
<source>Br Heart J</source>
<year>1960</year>; <volume>22</volume>: <fpage>1</fpage>&#x2013;<lpage>16</lpage><pub-id pub-id-type="pmid">13804406</pub-id></mixed-citation>
      </ref>
      <ref id="bibr4-0961203313497116">
        <label>4</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tincani</surname><given-names>A</given-names></name><name><surname>Rebaioli</surname><given-names>CB</given-names></name><name><surname>Taglietti</surname><given-names>M</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>
<article-title>Heart involvement in systemic lupus erythematosus,
anti-phospholipid syndrome and neonatal lupus</article-title>. <source>Rheumatology
(Oxford)</source>
<year>2006</year>; <volume>45 (Suppl 4)</volume>:
<fpage>iv8</fpage>&#x2013;<lpage>iv13</lpage><pub-id pub-id-type="pmid">16980725</pub-id></mixed-citation>
      </ref>
      <ref id="bibr5-0961203313497116">
        <label>5</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>G</given-names></name><name><surname>Bodet</surname><given-names>J</given-names></name><name><surname>Webb</surname><given-names>K</given-names></name><etal/></person-group>
<article-title>Systemic lupus erythematosis presenting as isolated
congestive heart failure</article-title>. <source>J Rheumatol</source>
<year>1985</year>; <volume>12</volume>:
<fpage>1182</fpage>&#x2013;<lpage>1185</lpage><pub-id pub-id-type="pmid">4093927</pub-id></mixed-citation>
      </ref>
      <ref id="bibr6-0961203313497116">
        <label>6</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Singh</surname><given-names>JA</given-names></name><name><surname>Woodard</surname><given-names>PK</given-names></name><name><surname>D&#xE1;vila-Rom&#xE1;n</surname><given-names>VG</given-names></name><etal/></person-group>
<article-title>Cardiac magnetic resonance imaging abnormalities in
systemic lupus erythematosus: A preliminary report</article-title>.
<source>Lupus</source>
<year>2005</year>; <volume>14</volume>: <fpage>137</fpage>&#x2013;<lpage>144</lpage><pub-id pub-id-type="pmid">15751818</pub-id></mixed-citation>
      </ref>
      <ref id="bibr7-0961203313497116">
        <label>7</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Logar</surname><given-names>D</given-names></name><name><surname>Kveder</surname><given-names>T</given-names></name><name><surname>Rozman</surname><given-names>B</given-names></name><name><surname>Dobovisek</surname><given-names>J</given-names></name></person-group>
<article-title>Possible association between anti-Ro antibodies and
myocarditis or cardiac conduction defects in adults with systemic lupus
erythematosus</article-title>. <source>Ann Rheum Dis</source>
<year>1990</year>; <volume>49</volume>: <fpage>627</fpage>&#x2013;<lpage>629</lpage><pub-id pub-id-type="pmid">2396870</pub-id></mixed-citation>
      </ref>
      <ref id="bibr8-0961203313497116">
        <label>8</label>
        <mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Koopman</surname><given-names>WJ</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name></person-group>
<article-title>Systemic lupus erythematosus: Clinical aspects</article-title>. In:
<person-group person-group-type="editor"><name><surname>Koopman</surname><given-names>WJ</given-names></name></person-group> (ed.) <source>Arthritis and allied conditions</source>,
<publisher-name>Lipppincott, Williams and Wilkins, PA, USA, 14th
edition</publisher-name>, <year>2001</year>, pp.
<fpage>1455</fpage>&#x2013;<lpage>1479</lpage></mixed-citation>
      </ref>
      <ref id="bibr9-0961203313497116">
        <label>9</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shoenfeld</surname><given-names>Y</given-names></name><name><surname>Gerli</surname><given-names>R</given-names></name><name><surname>Doria</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Accelerated atherosclerosis in autoimmune rheumatic
diseases</article-title>. <source>Circulation</source>
<year>2005</year>; <volume>112</volume>:
<fpage>3337</fpage>&#x2013;<lpage>3347</lpage><pub-id pub-id-type="pmid">16301360</pub-id></mixed-citation>
      </ref>
      <ref id="bibr10-0961203313497116">
        <label>10</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rhew</surname><given-names>EY</given-names></name><name><surname>Ramsey-Goldman</surname><given-names>R</given-names></name></person-group>
<article-title>Premature atherosclerotic disease in systemic lupus
erythematosus &#x2013; role of inflammatory mechanisms</article-title>. <source>Autoimmun
Rev</source>
<year>2006</year>; <volume>5</volume>: <fpage>101</fpage>&#x2013;<lpage>105</lpage><pub-id pub-id-type="pmid">16431336</pub-id></mixed-citation>
      </ref>
      <ref id="bibr11-0961203313497116">
        <label>11</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bruce</surname><given-names>IN</given-names></name></person-group>
<article-title>Cardiovascular disease in lupus patients: Should all
patients be treated with statins and aspirin?</article-title>
<source>Best Pract Res Clin Rheumatol</source>
<year>2005</year>; <volume>19</volume>: <fpage>823</fpage>&#x2013;<lpage>838</lpage><pub-id pub-id-type="pmid">16150405</pub-id></mixed-citation>
      </ref>
      <ref id="bibr12-0961203313497116">
        <label>12</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Manzi</surname><given-names>S</given-names></name><name><surname>Meilahn</surname><given-names>EN</given-names></name><name><surname>Rairie</surname><given-names>JE</given-names></name><etal/></person-group>
<article-title>Age-specific incidence rates of myocardial infarction and
angina in women with systemic lupus erythematosus: Comparison with the Framingham
Study</article-title>. <source>Am J Epidemiol</source>
<year>1997</year>; <volume>145</volume>: <fpage>408</fpage>&#x2013;<lpage>415</lpage><pub-id pub-id-type="pmid">9048514</pub-id></mixed-citation>
      </ref>
      <ref id="bibr13-0961203313497116">
        <label>13</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cervera</surname><given-names>R</given-names></name><name><surname>Piette</surname><given-names>JC</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Antiphospholipid syndrome: Clinical and immunologic
manifestations and patterns of disease expression in a cohort of 1,000
patients</article-title>. <source>Arthritis Rheum</source>
<year>2002</year>; <volume>46</volume>:
<fpage>1019</fpage>&#x2013;<lpage>1027</lpage><pub-id pub-id-type="pmid">11953980</pub-id></mixed-citation>
      </ref>
      <ref id="bibr14-0961203313497116">
        <label>14</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hojnik</surname><given-names>M</given-names></name><name><surname>George</surname><given-names>J</given-names></name><name><surname>Ziporen</surname><given-names>L</given-names></name><name><surname>Shoenfeld</surname><given-names>Y</given-names></name></person-group>
<article-title>Heart valve involvement (Libman-Sacks endocarditis) in the
antiphospholipid syndrome</article-title>. <source>Circulation</source>
<year>1996</year>; <volume>93</volume>:
<fpage>1579</fpage>&#x2013;<lpage>1587</lpage><pub-id pub-id-type="pmid">8608627</pub-id></mixed-citation>
      </ref>
      <ref id="bibr15-0961203313497116">
        <label>15</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Turiel</surname><given-names>M</given-names></name><name><surname>Muzzupappa</surname><given-names>S</given-names></name><name><surname>Gottardi</surname><given-names>B</given-names></name><name><surname>Crema</surname><given-names>C</given-names></name><name><surname>Sarzi-Puttini</surname><given-names>P</given-names></name><name><surname>Rossi</surname><given-names>E</given-names></name></person-group>
<article-title>Evaluation of cardiac abnormalities and embolic sources in
primary antiphospholipid syndrome by transesophageal echocardiography</article-title>.
<source>Lupus</source>
<year>2000</year>; <volume>9</volume>: <fpage>406</fpage>&#x2013;<lpage>412</lpage><pub-id pub-id-type="pmid">10981643</pub-id></mixed-citation>
      </ref>
      <ref id="bibr16-0961203313497116">
        <label>16</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Erdogan</surname><given-names>D</given-names></name><name><surname>Goren</surname><given-names>MT</given-names></name><name><surname>Diz-Kucukkaya</surname><given-names>R</given-names></name><name><surname>Inanc</surname><given-names>M</given-names></name></person-group>
<article-title>Assessment of cardiac structure and left atrial appendage
functions in primary antiphospholipid syndrome: A transesophageal echocardiographic
study</article-title>. <source>Stroke</source>
<year>2005</year>; <volume>36</volume>: <fpage>592</fpage>&#x2013;<lpage>596</lpage><pub-id pub-id-type="pmid">15677581</pub-id></mixed-citation>
      </ref>
      <ref id="bibr17-0961203313497116">
        <label>17</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Veres</surname><given-names>K</given-names></name><name><surname>Lakos</surname><given-names>G</given-names></name><name><surname>Ker&#xE9;nyi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Antiphospholipid antibodies in acute coronary
syndrome</article-title>. <source>Lupus</source>
<year>2004</year>; <volume>13</volume>: <fpage>423</fpage>&#x2013;<lpage>427</lpage><pub-id pub-id-type="pmid">15303568</pub-id></mixed-citation>
      </ref>
      <ref id="bibr18-0961203313497116">
        <label>18</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Petri</surname><given-names>M</given-names></name></person-group>
<article-title>The lupus anticoagulant is a risk factor for myocardial
infarction (but not atherosclerosis): Hopkins Lupus Cohort</article-title>.
<source>Throm Res</source>
<year>2004</year>; <volume>114</volume>: <fpage>593</fpage>&#x2013;<lpage>595</lpage></mixed-citation>
      </ref>
      <ref id="bibr19-0961203313497116">
        <label>19</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ranzolin</surname><given-names>A</given-names></name><name><surname>Bohn</surname><given-names>JM</given-names></name><name><surname>Norman</surname><given-names>GL</given-names></name><etal/></person-group>
<article-title>Anti-beta2-glycoprotein I antibodies as risk factors for
acute myocardial infarction [in English and Portuguese]</article-title>. <source>Arq
Bras Cardiol</source>
<year>2004</year>; <volume>83</volume>:
<fpage>141&#x2013;144</fpage>&#x2013;<lpage>137&#x2013;140</lpage><pub-id pub-id-type="pmid">15322656</pub-id></mixed-citation>
      </ref>
      <ref id="bibr20-0961203313497116">
        <label>20</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Keating</surname><given-names>RJ</given-names></name><name><surname>Bhatia</surname><given-names>S</given-names></name><name><surname>Amin</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>A</given-names></name><name><surname>Sinak</surname><given-names>LJ</given-names></name><name><surname>Edwards</surname><given-names>WD</given-names></name></person-group>
<article-title>Hydroxychloroquine-induced cardiotoxicity in a 39-year-old
woman with systemic lupus erythematosus and systolic dysfunction</article-title>.
<source>J Am Soc Echocardiogr</source>
<year>2005</year>; <volume>18</volume>: <fpage>981</fpage>&#x2013;<lpage>981</lpage><pub-id pub-id-type="pmid">16153529</pub-id></mixed-citation>
      </ref>
      <ref id="bibr21-0961203313497116">
        <label>21</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nord</surname><given-names>JE</given-names></name><name><surname>Shah</surname><given-names>PK</given-names></name><name><surname>Rinaldi</surname><given-names>RZ</given-names></name><name><surname>Weisman</surname><given-names>MH</given-names></name></person-group>
<article-title>Hydroxychloroquine cardiotoxicity in systemic lupus
erythematosus: A report of 2 cases and review of the literature</article-title>.
<source>Semin Arthritis Rheum</source>
<year>2004</year>; <volume>33</volume>: <fpage>336</fpage>&#x2013;<lpage>351</lpage><pub-id pub-id-type="pmid">15079764</pub-id></mixed-citation>
      </ref>
      <ref id="bibr22-0961203313497116">
        <label>22</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Saussine</surname><given-names>A</given-names></name><name><surname>Loriot</surname><given-names>MA</given-names></name><name><surname>Picard</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>Chloroquine cardiotoxicity in long-term lupus therapy in
two patients [in French]</article-title>. <source>Ann Dermatol Venereol</source>
<year>2009</year>; <volume>136</volume>: <fpage>530</fpage>&#x2013;<lpage>535</lpage><pub-id pub-id-type="pmid">19560616</pub-id></mixed-citation>
      </ref>
      <ref id="bibr23-0961203313497116">
        <label>23</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>CY</given-names></name><name><surname>Wang</surname><given-names>FL</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name></person-group>
<article-title>Chronic hydroxychloroquine use associated with QT
prolongation and refractory ventricular arrhythmia</article-title>. <source>Clin Toxicol
(Phila)</source>
<year>2006</year>; <volume>44</volume>: <fpage>173</fpage>&#x2013;<lpage>175</lpage><pub-id pub-id-type="pmid">16615675</pub-id></mixed-citation>
      </ref>
      <ref id="bibr24-0961203313497116">
        <label>24</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>August</surname><given-names>C</given-names></name><name><surname>Holzhausen</surname><given-names>HJ</given-names></name><name><surname>Schmoldt</surname><given-names>A</given-names></name><name><surname>Pompecki</surname><given-names>R</given-names></name><name><surname>Schroder</surname><given-names>S</given-names></name></person-group>
<article-title>Histological and ultrastructural findings in
chloroquine-induced cardiomyopathy</article-title>. <source>J Mol Med (Berl)</source>
<year>1995</year>; <volume>73</volume>: <fpage>73</fpage>&#x2013;<lpage>77</lpage><pub-id pub-id-type="pmid">7627632</pub-id></mixed-citation>
      </ref>
      <ref id="bibr25-0961203313497116">
        <label>25</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cervera</surname><given-names>A</given-names></name><name><surname>Espinosa</surname><given-names>G</given-names></name><name><surname>Font</surname><given-names>J</given-names></name><name><surname>Ingelmo</surname><given-names>M</given-names></name></person-group>
<article-title>Cardiac toxicity secondary to long term treatment with
chloroquine</article-title>. <source>Ann Rheum Dis</source>
<year>2001</year>; <volume>60</volume>: <fpage>301</fpage>&#x2013;<lpage>301</lpage><pub-id pub-id-type="pmid">11245140</pub-id></mixed-citation>
      </ref>
      <ref id="bibr26-0961203313497116">
        <label>26</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baguet</surname><given-names>JP</given-names></name><name><surname>Tremel</surname><given-names>F</given-names></name><name><surname>Fabre</surname><given-names>M</given-names></name></person-group>
<article-title>Chloroquine cardiomyopathy with conduction
disorders</article-title>. <source>Heart</source>
<year>1999</year>; <volume>81</volume>: <fpage>221</fpage>&#x2013;<lpage>223</lpage><pub-id pub-id-type="pmid">9922366</pub-id></mixed-citation>
      </ref>
      <ref id="bibr27-0961203313497116">
        <label>27</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ratliff</surname><given-names>NB</given-names></name><name><surname>Estes</surname><given-names>ML</given-names></name><name><surname>Myles</surname><given-names>JL</given-names></name><name><surname>Shirey</surname><given-names>EK</given-names></name><name><surname>McMahon</surname><given-names>JT</given-names></name></person-group>
<article-title>Diagnosis of chloroquine cardiomyopathy by endomyocardial
biopsy</article-title>. <source>N Engl J Med</source>
<year>1987</year>; <volume>316</volume>: <fpage>191</fpage>&#x2013;<lpage>193</lpage><pub-id pub-id-type="pmid">3796692</pub-id></mixed-citation>
      </ref>
      <ref id="bibr28-0961203313497116">
        <label>28</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sanmart&#xED;</surname><given-names>R</given-names></name><name><surname>G&#xF3;mez-Casanovas</surname><given-names>E</given-names></name><name><surname>Sol&#xE9;</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Prevalence of silent amyloidosis in RA and its clinical
significance</article-title>. <source>J Rheumatol</source>
<year>2004</year>; <volume>31</volume>: <fpage>1013</fpage>&#x2013;<lpage>1014</lpage>
<comment>author reply 1014</comment><pub-id pub-id-type="pmid">15124276</pub-id></mixed-citation>
      </ref>
      <ref id="bibr29-0961203313497116">
        <label>29</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brady</surname><given-names>RO</given-names></name><name><surname>Gal</surname><given-names>AE</given-names></name><name><surname>Bradley</surname><given-names>RM</given-names></name><name><surname>Martensson</surname><given-names>E</given-names></name><name><surname>Warshaw</surname><given-names>AL</given-names></name><name><surname>Laster</surname><given-names>L</given-names></name></person-group>
<article-title>Enzymatic defect in Fabry&#x2019;s disease. Ceramidetrihexosidase
deficiency</article-title>. <source>N Engl J Med</source>
<year>1967</year>; <volume>276</volume>:
<fpage>1163</fpage>&#x2013;<lpage>1167</lpage><pub-id pub-id-type="pmid">6023233</pub-id></mixed-citation>
      </ref>
      <ref id="bibr30-0961203313497116">
        <label>30</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Das</surname><given-names>AM</given-names></name><name><surname>Naim</surname><given-names>HY</given-names></name></person-group>
<article-title>Biochemical basis of Fabry disease with emphasis on
mitochondrial function and protein trafficking</article-title>. <source>Adv Clin
Chem</source>
<year>2009</year>; <volume>49</volume>: <fpage>57</fpage>&#x2013;<lpage>71</lpage><pub-id pub-id-type="pmid">19947355</pub-id></mixed-citation>
      </ref>
      <ref id="bibr31-0961203313497116">
        <label>31</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mechtler</surname><given-names>TP</given-names></name><name><surname>Stary</surname><given-names>S</given-names></name><name><surname>Metz</surname><given-names>TF</given-names></name><etal/></person-group>
<article-title>Neonatal screening for lysosomal storage disorders:
Feasibility and incidence from a nationwide study in Austria</article-title>.
<source>Lancet</source>
<year>2012</year>; <volume>379</volume>: <fpage>335</fpage>&#x2013;<lpage>341</lpage><pub-id pub-id-type="pmid">22133539</pub-id></mixed-citation>
      </ref>
      <ref id="bibr32-0961203313497116">
        <label>32</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>B</given-names></name></person-group>
<article-title>Fabry disease: Recent advances in pathology, diagnosis,
treatment and monitoring</article-title>. <source>Orphanet J Rare Dis</source>
<year>2009</year>; <volume>4</volume>: <fpage>21</fpage>&#x2013;<lpage>21</lpage><pub-id pub-id-type="pmid">19818152</pub-id></mixed-citation>
      </ref>
      <ref id="bibr33-0961203313497116">
        <label>33</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rahman</surname><given-names>P</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Wither</surname><given-names>J</given-names></name><name><surname>Silver</surname><given-names>MD</given-names></name></person-group>
<article-title>Coexistence of Fabry&#x2019;s disease and systemic lupus
erythematosus</article-title>. <source>Clin Exp Rheumatol</source>
<year>1998</year>; <volume>16</volume>: <fpage>475</fpage>&#x2013;<lpage>478</lpage><pub-id pub-id-type="pmid">9706432</pub-id></mixed-citation>
      </ref>
      <ref id="bibr34-0961203313497116">
        <label>34</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Majima</surname><given-names>K</given-names></name><name><surname>Ishizaki</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>A case of Fabry&#x2019;s disease associated with lupus nephritis
[in Japanese]</article-title>. <source>Nihon Jinzo Gakkai Shi</source>
<year>1992</year>; <volume>34</volume>:
<fpage>1189</fpage>&#x2013;<lpage>1194</lpage><pub-id pub-id-type="pmid">1338214</pub-id></mixed-citation>
      </ref>
      <ref id="bibr35-0961203313497116">
        <label>35</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rosenmann</surname><given-names>E</given-names></name><name><surname>Kobrin</surname><given-names>I</given-names></name><name><surname>Cohen</surname><given-names>T</given-names></name></person-group>
<article-title>Kidney involvement in systemic lupus erythematosus and
Fabry&#x2019;s disease</article-title>. <source>Nephron</source>
<year>1983</year>; <volume>34</volume>: <fpage>180</fpage>&#x2013;<lpage>184</lpage><pub-id pub-id-type="pmid">6410291</pub-id></mixed-citation>
      </ref>
      <ref id="bibr36-0961203313497116">
        <label>36</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Arias Mart&#xED;nez</surname><given-names>N</given-names></name><name><surname>Barbado Hern&#xE1;ndez</surname><given-names>FJ</given-names></name><name><surname>P&#xE9;rez Mart&#xED;n</surname><given-names>G</given-names></name><name><surname>P&#xE9;rez de Ayala</surname><given-names>C</given-names></name><name><surname>Casal Esteban</surname><given-names>V</given-names></name><name><surname>V&#xE1;zquez Rodr&#xED;guez</surname><given-names>JJ</given-names></name></person-group>
<article-title>Fabry&#x2019;s disease associated with rheumatoid arthritis.
Multisystemic crossroads [in Spanish]</article-title>. <source>An Med Interna</source>
<year>2003</year>; <volume>20</volume>: <fpage>28</fpage>&#x2013;<lpage>30</lpage><pub-id pub-id-type="pmid">12666306</pub-id></mixed-citation>
      </ref>
      <ref id="bibr37-0961203313497116">
        <label>37</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinez</surname><given-names>P</given-names></name><name><surname>Aggio</surname><given-names>M</given-names></name><name><surname>Rozenfeld</surname><given-names>P</given-names></name></person-group>
<article-title>High incidence of autoantibodies in Fabry disease
patients</article-title>. <source>J Inherit Metab Dis</source>
<year>2007</year>; <volume>30</volume>: <fpage>365</fpage>&#x2013;<lpage>369</lpage><pub-id pub-id-type="pmid">17458709</pub-id></mixed-citation>
      </ref>
      <ref id="bibr38-0961203313497116">
        <label>38</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ames</surname><given-names>P</given-names></name><name><surname>Margarita</surname><given-names>A</given-names></name><name><surname>Alves</surname><given-names>J</given-names></name></person-group>
<article-title>Antiphospholipid antibodies and atherosclerosis: Insights
from systemic lupus erythematosus and primary antiphospholipid syndrome</article-title>.
<source>Clin Rev Allergy Immunol</source>
<year>2009</year>; <volume>37</volume>: <fpage>29</fpage>&#x2013;<lpage>35</lpage><pub-id pub-id-type="pmid">18987784</pub-id></mixed-citation>
      </ref>
      <ref id="bibr39-0961203313497116">
        <label>39</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jury</surname><given-names>EC</given-names></name><name><surname>Flores-Borja</surname><given-names>F</given-names></name><name><surname>Kabouridis</surname><given-names>PS</given-names></name></person-group>
<article-title>Lipid rafts in T cell signalling and
disease</article-title>. <source>Semin Cell Dev Biol</source>
<year>2007</year>; <volume>18</volume>: <fpage>608</fpage>&#x2013;<lpage>615</lpage><pub-id pub-id-type="pmid">17890113</pub-id></mixed-citation>
      </ref>
      <ref id="bibr40-0961203313497116">
        <label>40</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Skaggs</surname><given-names>BJ</given-names></name><name><surname>Hahn</surname><given-names>BH</given-names></name><name><surname>McMahon</surname><given-names>M</given-names></name></person-group>
<article-title>Accelerated atherosclerosis in patients with SLE &#x2013;
mechanisms and management</article-title>. <source>Nat Rev Rheumatol</source>
<year>2012</year>; <volume>8</volume>: <fpage>214</fpage>&#x2013;<lpage>223</lpage><pub-id pub-id-type="pmid">22331061</pub-id></mixed-citation>
      </ref>
      <ref id="bibr41-0961203313497116">
        <label>41</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mehta</surname><given-names>A</given-names></name><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Elliott</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Enzyme replacement therapy with agalsidase alfa in
patients with Fabry&#x2019;s disease: An analysis of registry data</article-title>.
<source>Lancet</source>
<year>2009</year>; <volume>374</volume>:
<fpage>1986</fpage>&#x2013;<lpage>1996</lpage><pub-id pub-id-type="pmid">19959221</pub-id></mixed-citation>
      </ref>
      <ref id="bibr42-0961203313497116">
        <label>42</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Spinelli</surname><given-names>L</given-names></name><name><surname>Pisani</surname><given-names>A</given-names></name><name><surname>Sabbatini</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Enzyme replacement therapy with agalsidase &#x3B2; improves
cardiac involvement in Fabry&#x2019;s disease</article-title>. <source>Clin Genet</source>
<year>2004</year>; <volume>66</volume>: <fpage>158</fpage>&#x2013;<lpage>165</lpage><pub-id pub-id-type="pmid">15253767</pub-id></mixed-citation>
      </ref>
      <ref id="bibr43-0961203313497116">
        <label>43</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shen</surname><given-names>JS</given-names></name><name><surname>Meng</surname><given-names>XL</given-names></name><name><surname>Moore</surname><given-names>DF</given-names></name><etal/></person-group>
<article-title>Globotriaosylceramide induces oxidative stress and
up-regulates cell adhesion molecule expression in Fabry disease endothelial
cells</article-title>. <source>Mol Genet Metab</source>
<year>2008</year>; <volume>95</volume>: <fpage>163</fpage>&#x2013;<lpage>168</lpage><pub-id pub-id-type="pmid">18707907</pub-id></mixed-citation>
      </ref>
      <ref id="bibr44-0961203313497116">
        <label>44</label>
        <mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mellor</surname><given-names>HR</given-names></name><name><surname>Neville</surname><given-names>DC</given-names></name><name><surname>Harvey</surname><given-names>DJ</given-names></name><name><surname>Platt</surname><given-names>FM</given-names></name><name><surname>Dwek</surname><given-names>RA</given-names></name><name><surname>Butters</surname><given-names>TD</given-names></name></person-group>
<article-title>Cellular effects of deoxynojirimycin analogues: Inhibition
of N-linked oligosaccharide processing and generation of free glucosylated
oligosaccharides</article-title>. <source>Biochem J</source>
<year>2004</year>; <volume>381</volume>(<issue>Pt 3</issue>):
<fpage>867</fpage>&#x2013;<lpage>875</lpage><pub-id pub-id-type="pmid">15128289</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
